Prophylactic management of cerebral vasospasm with clazosentan in real clinical practice: a single-center retrospective cohort study

IntroductionClazosentan, a selective endothelin receptor subtype A antagonist, reduces vasospasm-related morbidity and all-cause mortality following aneurysmal subarachnoid hemorrhage (SAH) in the Japanese population, as demonstrated by a recent randomized phase 3 trial. However, evidence to suggest...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй

Үндсэн зохиолчид:	Hiroyuki Sakata, Atsushi Kanoke, Hiroki Uchida, Shinya Haryu, Shunsuke Omodaka, Naoto Kimura, Masahiro Yoshida, Kuniyasu Niizuma, Teiji Tominaga, Hidenori Endo
Формат:	Artigo
Хэл сонгох:	Inglês
Хэвлэсэн:	Frontiers Media S.A. 2024-06-01
Цуврал:	Frontiers in Neurology
Нөхцлүүд:	subarachnoid hemorrhage cerebral vasospasm delayed cerebral ischemia delayed ischemic neurologic deficit clazosentan endothelin
Онлайн хандалт:	https://www.frontiersin.org/articles/10.3389/fneur.2024.1413632/full
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!